Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced the launch of oncoReveal® Lymphoid, a ...

The prognosis for patients with myeloid/lymphoid neoplasms with FGFR1 rearrangements is poor, and treatment options are limited. In a phase II study of these patients, the overall complete response ...

New research suggests that DNA variants help predict toxicity and response in CAR T-cell therapy for large B-cell lymphoma.

Lymphoid-derived conventional dendritic cells (L-cDCs) may play a unique function associated with immune suppression and allergy induction, as reported by researchers from Japan. Long thought to arise ...

The FDA approves generic dasatinib tablets, enhancing access and affordability for treating chronic myeloid leukemia and acute lymphoblastic leukemia.

The first comprehensive map of the dramatic changes that take place in the blood system over the course of the human lifetime could have implications for the treatment of acute myeloid leukemia and ...

We often think of blood as the uniform red liquid encountered after a kitchen accident or at the doctor’s office. While this is true, on a microscopic level blood is made up of highly heterogeneous ...

Somatic mutations with effects similar to those seen with VEXAS syndrome are increasingly seen as possible drivers of ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced that the Company will present new data from across its oncology portfolio at the 2024 American Society of Hematology (ASH) ...

September is Leukemia and Lymphoma Awareness Month. An estimated 1,629,474 people in the United States (US) are living with or in remission from leukemia, lymphoma, myeloma, myelodysplastic syndromes ...

An update from Marker Therapeutics ( ($MRKR) ) is now available. Marker Therapeutics reported promising results from its APOLLO study, showing a ...